AcuCort Q2 FY26 net loss widens to SEK 8.2 million; revenue rises to SEK 1.16 million

Reuters2026/08/19 06:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AcuCort posted Q2 revenue of SEK 1.16 million, more than doubled from the year-earlier quarter.
Net loss widened to SEK 8.2 million, with loss per share improving to SEK 0.03.
Cash totaled SEK 10.37 million at quarter-end.
FDA agreement on the iPSP cleared remaining studies needed for a planned US NDA filing in 2026.
CEO Jonas Jönmark said Zeqmelit interest strengthened after the Glenmark deal, with talks deepening following BIO International Convention meetings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190220BITN____UKPR__SV_20260818-BIT-9081-0) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AcuCort Q2 FY26 net loss widens to SEK 8.2 million; revenue rises to SEK 1.16 million

You may also like

Crypto prices